Biotech and Pharma M&A in 2020

by | Feb 17, 2021

Biotech and pharma M&A total deal values slumped in 2020, despite an active year in life sciences dealmaking, with no big standout biopharma deals until late in the second half of the year. It could also be argued that big M&A deals were put on a backburner as Big Pharma, a major buyer, rushed to develop vaccines and therapeutics to combat and stem the COVID-19 pandemic and made only bolt-on acquisitions. Indeed, it wasn’t until mid-December when AstraZeneca announced it would acquire rare disease drug developer Alexion for $39 billion that total deal values rose to anywhere near industry expectations at the beginning of the year.

We looked at the extensive DealForma database to see how life sciences M&A, mainly biotech and pharma M&A, activity shaped up in 2020 in more detail.

 

The Takeaways:

  • 2020 was the most active year to date for biopharma M&A as far as number of transactions but not in total deal value as smaller bolt-on acquisitions dominated deal flow.
  • Average M&A upfront cash and equity values fell to $1.4 billion, while median upfront values dropped to $61 million, the lowest level over the past 13 years, due in part to lack of mega deals.
  • Buyers focused on innovative private companies (81), diagnostics providers (32), and tools and contract services companies (168).
Biopharma Platform Medtech Diagnostics M&A through 2020

Total M&A deal values of biopharma therapeutics and platforms, diagnostics, and medtech companies dropped 26 percent to $190.9 billion, after steadily rising for three years running, while the total number of acquisitions, acquisition options, and reverse mergers continued to rise reaching 384 completed or active deals, up 10 percent from 2019. While most of the value was in cash and equity upfront with 10 percent contingent on milestones, only 6 percent was contingent on milestones in 2019.

Although the COVID-19 pandemic hampered face-to-face meetings, life sciences partnering and capital raising activities were robust, including a sizzling IPO market, while M&A stayed in the doldrums the first half of the year. It was not until September, when Gilead Sciences disclosed that it was buying Immunomedics for $21 billion to beef up its oncology pipeline that things started to heat up with 219 deals announced in the third and fourth quarters of 2020 accounting for $173 billion in total deal value.

Quarterly Biopharma, Platform, Medtech, and Diagnostics M&A

Average upfront cash and equity of 2020 M&A deals at $1.4 billion was 32 percent less than the average upfront cash and equity of 2019 deals at $1.8 billion, due in part to the two megadeals in 2019 when Bristol-Myers Squibb paid $74 billion for Celgene and AbbVie paid $63 billion for Allergan. The paucity of big dollar M&A deals during most of 2020 also caused median upfront cash and equity values to drop 39 percent to $61 million in 2020, compared to $100 million in 2019.

Quarterly Biopharma M&A Median Upfront Cash and Equity

Big Pharma continued to have a major presence among the top acquirers in 2020 but some new names joined the list, including genomics firm Illumina, private equity firm Blackstone, and service providers Siemens Healthineers and Teladoc Health. Illumina snapped up Grail for $8 billion ahead of its planned IPO; Teladoc paid $18.5 billion for digital health company Livongo; Blackstone paid $4.7 billion for genetic testing company Ancestry.com; and Siemens acquired diagnostic and services provider Varian for $16.4 billion.

Top 20 M&A Buyers by Upfront Cash and Equity in 2020

As in many years past, the 30 transactions valued at $1 billion or more accounted for 91 percent of the total 2020 M&A deal values, and Gilead Sciences topped the list as the most active acquirer striking four deals in oncology and one in viral diseases.

Big Pharma Expands Presence in Rare Diseases

AstraZeneca made a strategic move into the rare disease/orphan therapeutics space with the acquisition of Alexion in December for $39 billion, following a steady march by Big Pharma into precision genetic medicines and targeted therapies. Between Bayer’s deal to buy gene therapy biotech Asklepios at the end of October for $2 billion upfront and another $2 billion based on potential success-based milestones and the end of the year, life sciences M&A realized $67 billion in total deal values, more than one third of the year’s total. Of that amount $45 billion was in four rare disease/orphan drug deals.

Want data for your analysis? Want us to do it? Subscribers get both.

Schedule your demo of the DealForma database to see how we help you get better reports done faster.

25,544

Deal Profiles

15,147

Funding Rounds

28,034

Company Profiles

17,936

Product Profiles

119K+

Clinical Trials

3,982

Business Developers

Specifically for Biotech, Pharma, Device, and Diagnostics

CDMO and Services and Diagnostics Deals

In 2020, 44 percent of M&A targets were contract development, manufacturing, tools, and services companies, while private, small and mid-cap biopharmaceutical companies accounted for 30.5 percent of acquisitions. The number of CDMO and Services deals rose 26 percent in 2020, and total deal values doubled compared to the previous year.

Targeted therapies require diagnostic tests to determine the right patient populations, which have boosted the value of genetic testing companies and diagnostics makers in general. 2020 saw a 60 percent increase over 2019 in the number of M&A deals for diagnostic targets, and a 309 percent increase in average upfront cash and equity payments.

Share of M&A Deals by Target Company Type – 2008-2020

Private Biopharma Deals

Of the 27 deals valued at $1 billion and above, seven were for private biotech companies: Illumina’s $8 billion cash and stock acquisition of early cancer detection testing company Grail; Bayer’s $4 billion purchase of gene therapy biotech Asklepios, of which $2 billion was paid upfront; Merck’s $2.75 billion buyout of VelosBio for its phase 2 first-in-class ROR1 antibody drug conjugate; NovoNordisk’s $2.1 billion acquisition deal for Corvidia Therapeutics, which received $725 million of that upfront for its IL-6 targeted antibody in cardio-renal indications; Gilead Sciences’ $1.8 billion deal for German biotech MYR, which is developing peptide treatments for viral infections; Boehringer Ingelheim’s $1.4 billion buyout of oncology-focused NBE-Therapeutics; and Eli Lilly’s $1.2 billion acquisition of neurology-focused biotech Disarm Therapeutics, of which $135 million was paid upfront.

Private Biopharma M&A Rose in 2020

While it could be argued that a strong market for IPOs gave investors in private companies a favorable exit instead of selling the company, 81 private biotech companies were acquired in 2020 for a total deal value of $24.4 billion, $11.3 billion upfront and $13.1 billion in contingent payments, an almost 21 percent rise from the 67 private biotech acquisitions in 2019. While the average upfront cash and equity payment for these companies rose to $264 million, a gain of 56 percent over 2019, the median M&A upfront cash and equity for these companies dropped 13 percent to $46 million from $53 million in 2019.

Average Upfronts for Private Biopharma M&A Up 56% in 2020

Small and Mid-Cap Biopharma

Unlike private biopharma M&A, public company acquisitions usually involve paying the total value upfront. In 2020, at $102 billion in total M&A deal values, they also made up the largest portion of total deal values, up 85 percent from 2019, in 14 percent fewer deals. Contingent payments accounted for less than 1 percent, or $800 million, of that total.

Small and Mid-Cap Biopharma M&A Rose in 2020 in Total Values with Fewer Deals

Three deals drove the rise in deal values in the sector, accounting for $73 billion, or two thirds of the total M&A deal values of these companies: AstraZeneca’s acquisition of Alexion for $39 billion, Gilead Sciences buyout of Immunomedics for $21 million, and Bristol-Myers Squibb’s payout of $13.1 billion for MyoKardia. The average premium was 71 percent and ranged from 45 percent for Alexion, which had been pressured to sell itself by disgruntled shareholders, to 108 percent for Immunomedics.

These deals also drove the rise in the average upfront cash and equity paid for small and mid-cap companies, which skyrocketed 88 percent in 2020 compared to 2019, but didn’t affect the median upfront cash and equity, which dropped 6 percent from the previous year.

Median Upfronts for Small and Mid-Cap Biopharma M&A Drop 6% in 2020

Biopharma M&A in 2021

It is unclear whether or not Big Pharma will make a definitive purchase in 2021 to boost biotech and pharma M&A numbers. If the first 48 days of 2021 are any indication, expect to see a continuation of bolt-on acquisitions and smaller deals as the year moves forward, especially in the rare disease, neurology, and oncology space. The two biggest deals in 2021 so far are Jazz Pharma’s $7.2 billion acquisition of GW Pharma for its marketed drug to treat rare epileptic seizures, and Horizon Pharma’s $3.05 billion buyout of Viela Bio and its approved drug to treat the rare condition neuromyelitis optica spectrum disorder that leads to vision loss.

Development of treatments and vaccines combatting the COVID-19 pandemic and future pandemics is still front-and-center and may impact a Big Pharma purchase. Still, mid-cap biotechs such as BioMarin, Alnylam, and Sarepta continue to be talked about takeover targets. And as more companies focus on targeted and precision genetic medicines and build out manufacturing capabilities, it bodes well for a strong year ahead.

This article is a sample from the DealForma Quarterly Deal Trends Report provided to database customers. Data for this analysis was compiled using the DealForma biopharma deals database. We applied initial filters for mergers and acquisitions, therapeutic areas, modalities, asset stages at signing, and deal payment terms. From there, we exported the data to Excel and used pivot tables and charts to do the rest. All data are based on publicly disclosed figures. We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting dealforma.com to schedule your personalized demo.

Marie Daghlian is a freelance writer and editor who reports on the business of biotechnology and healthcare technologies and on rare diseases for Global Gene’s Rare Daily. She also covers the industry for Big4Bio, a daily newsletter focused on the four major biotech centers in the United States.

Chris Dokomajilar is the Founder / CEO of DealForma and has been an industry analyst for over a decade. He analyzed the data and produced the charts for this article. More about Chris.

More Research by DealForma

August 2022 Top Biopharma Deal: Sanofi – Innovent for Cancer Drugs SAR408701 and SAR444245

August 2022 Top Biopharma Deal: Sanofi – Innovent for Cancer Drugs SAR408701 and SAR444245

The top deal upfront for Aug 2022 was the Sanofi development and commercialization deal with Innovent for SAR408701 and SAR444245. Sanofi granted Innovent exclusive rights to develop and commercialize its SAR408701 (tusamitamab ravtansine) for the treatment of non-small cell lung cancer (NSCLC) and gastric cancer in China. Additionally, Sanofi and Innovent will co-develop SAR444245 for the treatment of multiple cancer drugs. Sanofi will invest EUR300M (approx. $306.6M) in Innovent up front at HK$42.42 (approx. $5.40) per share in Innovent common stock. Sanofi is eligible for EUR80M (approx. $81.7M) in development milestones plus royalties for SAR408701, while Innovent is eligible to receive EUR60M (approx. $61.3M) in development milestones and royalties for SAR444245.

read more
July 2022 Top Biopharma Deal: Orion – MSD for Prostate Cancer Drug ODM-208

July 2022 Top Biopharma Deal: Orion – MSD for Prostate Cancer Drug ODM-208

The top deal upfront for July 2022 was the Orion co-development and co-commercialization deal with MSD for ODM-208. Orion granted MSD rights to co-develop and co-commercialize ODM-208 for the treatment of metastatic castration-resistant prostate cancer. Orion and MSD have an option to convert the co-development and co-commercialization agreement into a global exclusive license to MSD. Upon exercising the option, MSD will retain the responsibility for all accrued and future development and commercialization expenses associated with the program. Orion will receive $290M up front, including $221M recognized as income, and approximately $60.3M reserved to cover Orion’s share of ODM-208 future development cost. Orion is eligible for undisclosed development and commercialization milestones, plus double-digit tiered royalties.

read more
June 2022 Top Biopharma Deal: Sanofi – Regeneron Pharmaceuticals for Cancer/Inflammation drug Libayo

June 2022 Top Biopharma Deal: Sanofi – Regeneron Pharmaceuticals for Cancer/Inflammation drug Libayo

The top deal upfront for June 2022 was the Sanofi development and commercialization deal with Regeneron for Libtayo (Amended Agreement). Sanofi granted Regeneron exclusive, worldwide rights to develop and commercialize Libtayo for the treatment of cancer. Regeneron and Sanofi signed a license agreement in 2015 to develop Libtayo. Sanofi will receive $900M up front and is eligible to receive up to a $100M milestone upon the first approval by either the FDA or EMA for Libtayo in combination with chemotherapy for first-line treatment of certain patients with NSCLC and up to $100M as a sales milestone in the next two years, plus 11% royalties.

read more
May 2022 Top Biopharma Deal: Dragonfly Therapeutics – Gilead Sciences NK cell engager for cancer/inflammation

May 2022 Top Biopharma Deal: Dragonfly Therapeutics – Gilead Sciences NK cell engager for cancer/inflammation

The top deal upfront for May 2022 was the Dragonfly Therapeutics development and commercialization deal with Gilead Sciences for solid tumors. Gilead has an exclusive, worldwide option to develop and commercialize additional NK cell engager programs by using its Tri-specific NK Engager (TriNKET) platform after the completion of certain preclinical activities. Dragonfly will receive $300M up front and is eligible to receive undisclosed opt-in payments and development, regulatory, and commercial milestones, plus up to 20% royalties.

read more
April 2022 Top Biopharma Deal: Harbour BioMed – AstraZeneca Bispecific Antibody for Cancer Treatment

April 2022 Top Biopharma Deal: Harbour BioMed – AstraZeneca Bispecific Antibody for Cancer Treatment

The top deal upfront for April 2022 was the Harbour BioMed development and commercialization deal with AstraZeneca for solid tumors. AstraZeneca will be responsible for all costs for development and commercialization. HBM will receive $25M up front and is eligible for up to $325M in development, regulatory, and commercial milestones, plus undisclosed tiered royalties.

read more
March 2022 Top Biopharma Deal: IGM Biosciences – Sanofi IgM Antibody Platform for Cancer and Immunology/Inflammation

March 2022 Top Biopharma Deal: IGM Biosciences – Sanofi IgM Antibody Platform for Cancer and Immunology/Inflammation

The top deal upfront for March 2022 was the IGM development and commercialization deal with Sanofi for cancer, immunology, and inflammation. IGM will receive $150M up front and is eligible to receive up to $6.015B in regulatory and commercial milestones, which includes $940M for each of 3 cancer targets and $1.065B for each of 3 immunology/inflammation targets. Additionally, Sanofi has expressed an interest in purchasing up to $100M of IGM non-voting common stock in a public financing.

read more
February 2022 Top Biopharma Deal:  Heidelberg – Huadong ATAC Candidates for Cancer Treatment

February 2022 Top Biopharma Deal: Heidelberg – Huadong ATAC Candidates for Cancer Treatment

The top deal upfront for February 2022 was the Heidelberg development and commercialization partnership with Huadong for HDP-101, HDP-103, and options for HDP-102 (CD37-ATAC) and HDP-104. Heidelberg will receive $20M up front and is eligible for up to $449M in milestones with additional $461M in option payments upon exercise. Additionally, Huadong will invest EUR 105M (35%) in Heidelberg, with an initial commitment of EUR 80M by purchasing 12,408,649 shares at EUR 6.44 per share.

read more
January 2022 Top Biopharma Deal: Beam – Pfizer In Vivo Base Editing and Delivery Programs for Rare Diseases

January 2022 Top Biopharma Deal: Beam – Pfizer In Vivo Base Editing and Delivery Programs for Rare Diseases

The top deal upfront for January 2022 was the Beam Therapeutics research partnership with Pfizer with an option to license in vivo base editing programs. Beam will receive $300M up front, up to up to $1.05B in development, regulatory, and sales milestones, plus royalties per licensed program. If Beam opts in to co-develop/co-promote a program, the companies will share cost and profits 65%/35% (Pfizer/Beam).

read more
November 2021 Top Biopharma Deal: Sanofi – Owkin artificial intelligence and federated learning platform to advance Sanofi’s oncology pipeline

November 2021 Top Biopharma Deal: Sanofi – Owkin artificial intelligence and federated learning platform to advance Sanofi’s oncology pipeline

The top deal upfront for November 2021 was the Owkin – Sanofi artificial intelligence and federated learning platform research partnership to advance Sanofi’s oncology pipeline. Owkin will receive a $180M upfront equity investment, $90M in R&D funding over 3 years, and is eligible for additional undisclosed R&D milestones.

read more

You met on Zoom. Now it's Deal Time.

With thousands of company profiles and a decade of deals specifically in biopharma and medtech, you'll take the guesswork out of deal comps. Schedule your customized demo to see how DealForma helps you win that term sheet with better data.